UK access routes, dated and sourced — a second dataset posts 61–83
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Correcting an out-of-date claim in this subcategory with a source and a date is more valuable than a new topic on the same question.
Collapsed as off-topic by two members at trust level 3 or above
Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.
Seconded. It reads as careful rather than confident, which is the right register.
Picking up post #62: that is the part I would want checked first.
Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.
The interesting part of this is the exception, and I do not understand the exception.
Cross-border arrangements: some people source from other EU countries. Rules on import for personal use are changing post-Brexit. Current status requires checking with UKVI.
Written from notes rather than memory, which is why the numbers are specific.
Occupational health screening: some UK occupations require medical checks. Disclosure of weight-loss medication might be relevant to employment screening; understand your obligations.
Cost comparisons should state whether they include the consultation, the device, the needles and the follow-up, because those differ between routes.
Narrowing post #66, because the general version has more than one answer.
Where guidance distinguishes between indications, quoting the indication is essential. The same compound has different positions under different indications.
That is a description of practice, not a recommendation of it.
Collapsed as off-topic by two members at trust level 3 or above
Everything in post #68 holds. The case it does not cover is the one I have.
Members outside these two jurisdictions reading this thread should note that none of it transfers, including the parts that sound general.
It is one reading of the data and not the only reasonable one.
Where the compound is supplied with a device, the device and the compound have separate availability positions and the device is more often the constraint.
The evidence for this is thinner than the way I have phrased it suggests.
Collapsed as off-topic by two members at trust level 3 or above
Coming back to post #71, because the follow-up matters more than the original answer.
Date the claim and say whether it is the United Kingdom or Ireland. They are different regulatory jurisdictions and the answer is frequently different.
I have changed my mind on this once already, so take it as current rather than settled.
Post #71 is right about the mechanism and I think understates the practical bit.
Cross-border movement between the two jurisdictions is not the same as domestic movement within either, and the rules are published rather than inferred.
That has been true for the cases I have seen and I have not seen many.
Taking post #74 at face value and following it one step further.
Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.
If it helps: the failure mode here is usually boring rather than dramatic.
I read post #76 twice before replying, because I had assumed the opposite.
Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed.
Same conclusion as the reply above, reached differently, which is mildly reassuring.
A dated first-hand account of a specific route is genuinely useful in this subcategory and should say which year and which service.
Post #76 describes the usual case. This is about the unusual one.
Correcting an out-of-date claim in this subcategory with a source and a date is more valuable than a new topic on the same question.
Take the reasoning and check the arithmetic; I do not always get it right.
Adding the measurement that post #79 says would settle it.
Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.
Cost comparisons should state whether they include the consultation, the device, the needles and the follow-up, because those differ between routes.
A qualification I should have led with rather than closed on.
Anyone quoting an eligibility threshold should say which document it comes from. The thresholds have changed and the old ones are still circulating.
It is the sort of thing that seems obvious in retrospect and was not at the time.
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Irish differences from the UK position
Posting this under the heading it deserves: Irish differences from the UK position Everything below is what sits behind that. Trying to establish the boundary conditions on irish differences. The general…
|
+62 | 66 | 993 | 21mo |
|
Pharmacy supply in the UK and the questions you will be asked
On the subject in the title: Pharmacy supply in the UK and the questions you will be asked Working notes rather than a conclusion. Asking about pharmacy supply on behalf of the question I keep seeing asked…
|
+95 | 105 | 1.3k | 4mo |
|
MHRA statements, read directly — the long version
On the subject in the title: MHRA statements, read directly — the long version Working notes rather than a conclusion. Asking about MHRA statements directly, because I have read four threads on it and each…
|
2 | 44k | 22mo | |
|
MHRA statements, read directly
MHRA statements, read directly Writing it up because I had to work it out twice and would rather nobody else did. Asking about MHRA statements directly, because I have read four threads on it and each…
|
+93 | 101 | 2.2k | 5mo |
|
About the UK & Ireland category
MHRA positions, NHS pathways, private prescriptions, and Irish differences. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a…
|
+3 | 7 | 357 | 3mo |
Related topics — sharing the tags MHRA, NHS, cost per milligram
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Pharmacy supply in the UK and the questions you will be asked
On the subject in the title: Pharmacy supply in the UK and the questions you will be asked Working notes rather than a conclusion. Asking about pharmacy supply on behalf of the question I keep seeing asked…
|
+95 | 105 | 1.3k | 4mo |
|
Price changes over 2025 and 2026, tabulated and dated
Posting this under the heading it deserves: Price changes over 2025 and 2026, tabulated and dated Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
|
+4 | 8 | 658 | 14mo |
|
Language barriers in accessing a prescription abroad
Language barriers in accessing a prescription abroad Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about language barriers in accessing in a thread last spring…
|
2 | 22k | 1h | |
|
About the International category
Country-by-country availability and legality, dated because it changes constantly. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
+6 | 11 | 240 | 22mo |
|
NHS criteria and how they are applied in practice — the long version
Posting this under the heading it deserves: NHS criteria and how they are applied in practice — the long version Everything below is what sits behind that. A narrow question about NHS criteria, deliberately…
|
+11 | 15 | 11k | 9mo |